Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival

Similar documents
Estimating and Modelling the Proportion Cured of Disease in Population Based Cancer Studies

Quantifying cancer patient survival; extensions and applications of cure models and life expectancy estimation

About me. An overview and some recent advances in statistical methods for population-based cancer survival analysis. Research interests

An overview and some recent advances in statistical methods for population-based cancer survival analysis

Estimating and modelling relative survival

The improved cure fraction for esophageal cancer in Linzhou city

Up-to-date survival estimates from prognostic models using temporal recalibration

Assessment of lead-time bias in estimates of relative survival for breast cancer

Sarwar Islam Mozumder 1, Mark J Rutherford 1 & Paul C Lambert 1, Stata London Users Group Meeting

M. J. Rutherford 1,*, T. M-L. Andersson 2, H. Møller 3, P.C. Lambert 1,2.

An overview and some recent advances in statistical methods for population-based cancer survival analysis

MEASURING CANCER CURE IN IRELAND

Downloaded from:

ASSESSMENT OF LEAD-TIME BIAS IN ESTIMATES OF RELATIVE SURVIVAL FOR BREAST CANCER

Supplementary Information for Avoidable deaths and random variation in patients survival

IJC International Journal of Cancer

Application of EM Algorithm to Mixture Cure Model for Grouped Relative Survival Data

Biological Cure. Margaret R. Stedman, Ph.D. MPH Angela B. Mariotto, Ph.D.

Cancer Incidence Predictions (Finnish Experience)

LOGO. Statistical Modeling of Breast and Lung Cancers. Cancer Research Team. Department of Mathematics and Statistics University of South Florida

Statistical Models for Censored Point Processes with Cure Rates

Biostatistics II

Measuring and predicting cancer incidence, prevalence and survival in Finland

Survival in Teenagers and Young. Adults with Cancer in the UK

Immortal Time Bias and Issues in Critical Care. Dave Glidden May 24, 2007

Spatiotemporal models for disease incidence data: a case study

Modelled prevalence. Marc COLONNA. January 22-23, 2014 Ispra

Survival analysis beyond the Cox-model

Temporal trends in the proportion cured for cancer of the colon and rectum: A population-based study using data from the Finnish Cancer Registry

Multivariate dose-response meta-analysis: an update on glst

Multi-state survival analysis in Stata

Statistical Methods for the Evaluation of Treatment Effectiveness in the Presence of Competing Risks

Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision

An Overview of Survival Statistics in SEER*Stat

Trends in Cure Fraction from Colorectal Cancer by Age and Tumour Stage Between 1975 and 2000, Using Population-based Data, Osaka, Japan

Original Article INTRODUCTION. Alireza Abadi, Farzaneh Amanpour 1, Chris Bajdik 2, Parvin Yavari 3

Recent Advances in Methods for Quantiles. Matteo Bottai, Sc.D.

Modeling unobserved heterogeneity in Stata

A Study on Type 2 Diabetes Mellitus Patients Using Regression Model and Survival Analysis Techniques

Lifetime vs. 10-year risk to allocate treatments for the primary prevention of cardiovascular disease

Methodology for the Survival Estimates

Issues for analyzing competing-risks data with missing or misclassification in causes. Dr. Ronny Westerman

Analysing population-based cancer survival settling the controversies

A Bayesian Perspective on Unmeasured Confounding in Large Administrative Databases

Statistical Models for Bias and Overdiagnosis in Prostate Cancer Screening

Estimands, Missing Data and Sensitivity Analysis: some overview remarks. Roderick Little

Statistical Science Issues in HIV Vaccine Trials: Part I

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.

Mathematical Framework for Health Risk Assessment

Measuring cancer survival in populations: relative survival vs cancer-specific survival

CANCER IN IRELAND with estimates for : ANNUAL REPORT OF THE NATIONAL CANCER REGISTRY

Age-standardised Net Survival & Cohort and Period Net Survival Estimates

Self-assessment test of prerequisite knowledge for Biostatistics III in R

Cancer in the Northern Territory :

Advanced IPD meta-analysis methods for observational studies

Trends in Cancer Survival in Scotland

Survival Analysis in Clinical Trials: The Need to Implement Improved Methodology

Investigation of relative survival from colorectal cancer between NHS organisations

Generation times in epidemic models

Generalized Mixed Linear Models Practical 2

Dynamic prediction using joint models for recurrent and terminal events: Evolution after a breast cancer

Trends in the Lifetime Risk of Developing Cancer in Ontario, Canada

cloglog link function to transform the (population) hazard probability into a continuous

Downloaded from irje.tums.ac.ir at 19:49 IRST on Monday January 14th 2019

Poisson regression. Dae-Jin Lee Basque Center for Applied Mathematics.

NEW METHODS FOR SENSITIVITY TESTS OF EXPLOSIVE DEVICES

Doing Thousands of Hypothesis Tests at the Same Time. Bradley Efron Stanford University

Estimating Incidence of HIV with Synthetic Cohorts and Varying Mortality in Uganda

Survival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

Should relative survival be used with lung cancer data?

Landmarking, immortal time bias and. Dynamic prediction

Age (continuous) Gender (0=Male, 1=Female) SES (1=Low, 2=Medium, 3=High) Prior Victimization (0= Not Victimized, 1=Victimized)

Chapter 13 Estimating the Modified Odds Ratio

Using dynamic prediction to inform the optimal intervention time for an abdominal aortic aneurysm screening programme

TWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL. Beth A.

Multivariable Cox regression. Day 3: multivariable Cox regression. Presentation of results. The statistical methods section

Individualized Treatment Effects Using a Non-parametric Bayesian Approach

Cross-validation. Miguel Angel Luque Fernandez Faculty of Epidemiology and Population Health Department of Non-communicable Diseases.

Cancer survival and prevalence in Tasmania

Deprivation and Cancer Survival in Scotland: Technical Report

EMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.

Benchmark Dose Modeling Cancer Models. Allen Davis, MSPH Jeff Gift, Ph.D. Jay Zhao, Ph.D. National Center for Environmental Assessment, U.S.

Extract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study

Trends in Irish cancer incidence with predictions to 2020

Lecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method

Research Designs and Potential Interpretation of Data: Introduction to Statistics. Let s Take it Step by Step... Confused by Statistics?

Common Misunderstandings of Survival Time Analysis

MODEL SELECTION STRATEGIES. Tony Panzarella

The Statistical Analysis of Failure Time Data

ALL CANCER (EXCLUDING NMSC)

CHAPTER 10 CANCER REPORT. Jeremy Chapman. and. Angela Webster

Modelling Spatially Correlated Survival Data for Individuals with Multiple Cancers

Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel

1 Cancer Council Queensland, Brisbane, Queensland, Australia.

Part [1.0] Introduction to Development and Evaluation of Dynamic Predictions

A note on Australian AIDS survival

Regression Output: Table 5 (Random Effects OLS) Random-effects GLS regression Number of obs = 1806 Group variable (i): subject Number of groups = 70

Midterm Exam ANSWERS Categorical Data Analysis, CHL5407H

Transcription:

An overview and some recent advances in statistical methods for population-based cancer survival analysis: relative survival, cure models, and flexible parametric models Paul W Dickman 1 Paul C Lambert 1,2 Sandra Eloranta 1 Therese Andersson 1 1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 2 Department of Health Sciences, University of Leicester, UK FMS Jubilee meeting, Utö, October 212 Overview Measures used in cancer control; why study patient survival. Intro to relative survival (excess mortality) and why it is the measure of choice for population-based cancer survival analysis. Flexible parametric models. The concept of statistical cure; cure models. Estimating crude and net probabilities of death. Partitioning excess mortality; estimating treatment related CVD mortality. Cool stuff that I definitely won t have time to talk about. Estimating the number of avoidable premature deaths. Loss in expectation of life. Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 2 r year 1, per y rate per 1 or mortality ncidence o In 12 11 1 9 8 7 6 5 4 3 2 1 Incidence Mortality Survival Lung cancer incidence, mortality and survival (age-standardised) England, 1982-28, by sex 1982 1986 199 1994 1998 22 26 Year of death / Men Women Women Men 1 9 8 7 6 5 4 3 2 1 al (%) ve surviva ear relativ Five-ye All-cause mortality for males with colon cancer and Finnish population Mortality Rate (per 1, person years) 8 7 6 5 4 3 2 1 General population Colon cancer patients 2 4 6 8 1 Age Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 3 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 4 Relative survival We estimate excess mortality: the difference between observed (all-cause) and expected mortality. excess = observed expected mortality mortality mortality Relative survival is the survival analog of excess mortality the relative survival ratio is defined as the observed survival in the patient group divided by the expected survival of a comparable group from the general population. relative survival ratio = observed survival proportion expected survival proportion Cervical cancer in New Zealand 1994 21 Life table estimates of patient survival Women diagnosed 1994-21 with follow-up to the end of 22 Interval- Interval- Effective specific specific Cumulative Cumulative Cumulative number observed relative observed expected relative I N D W at risk survival survival survival survival survival 1 1559 29 1559. 6594 7472 6594 8996 7472 2 135 125 177 1261.5 91 829 814 8192 945 3 148 58 172 962. 3971 4772 331 7362 5296 4 818 32 155 74 5679 6459 142 6574 263 5 631 23 148 557. 5871 6679 7246 5766 218 6 46 1 13 395. 7468 8284 5543 4972 913 7 32 5 129 255.5 843 8848 4261 4198 8219 8 186 3 134 119. 7479 845 2641 3312 713 9 49 1 48 25. 6 758 135 1869 5457 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 5 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 6 Relative survival example (skin melanoma) Modelling excess mortality Table 1: Number of cases (N) and 5-year observed (p), expected (p ), and relative (r) survival for males diagnosed with localised skin melanoma in Finland during 1985 1994. Age N p p r 15 29 67 47 93 54 3 44 273 56 82 72 45 59 53 24 43 74 6 74 449 79 15 33 75+ 2 96 5 84 Relative survival controls for the fact that expected mortality depends on demographic characteristics (age, sex, etc.). In addition, relative survival may, and usually does, depend on such factors. Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 7 Relative Survival Models h(t) = h (t) + λ(t) Observed Mortality Rate = Expected Mortality Rate + Excess Mortality Rate Cox model cannot be applied to model a difference in two rates. It is the observed mortality that drives the variance. Can use Poisson regression (Dickman et al. 24) [1]. Even better: flexible parametric models (Royston and Parmar 22 [2], Nelson et al. [3]). Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 8

Flexible Parametric Survival Models Quote from Sir David Cox (Reid 1994 [5]) Reid What do you think of the cottage industry that s grown up around [the Cox model]? First introduced by Royston and Parmar (22) [2]. Parametric estimate of the baseline hazard without the usual restrictions on the shape (i.e, flexible). Applicable for standard and relative survival models. Can fit relative survival cure models (Andersson 211) [4]. Once we have a parametric expression for the baseline hazard we derive other quantities of interest (e.g., survival, hazard ratio, hazard differences, expectation of life). Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 9 Cox In the light of further results one knows since, I think I would normally want to tackle the problem parametrically.... I m not keen on non-parametric formulations normally. Reid So if you had a set of censored survival data today, you might rather fit a parametric model, even though there was a feeling among the medical statisticians that that wasn t quite right. Cox That s right, but since then various people have shown that the answers are very insensitive to the parametric formulation of the underlying distribution. And if you want to do things like predict the outcome for a particular patient, it s much more convenient to do that parametrically. Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 1 Example: survival of patients diagnosed with colon carcinoma in Finland Patients diagnosed with colon carcinoma in Finland 1984 95. Potential follow-up to end of 1995; censored after 1 years. Outcome is death due to colon carcinoma. Interest is in the effect of clinical stage at diagnosis (distant metastases vs no distant metastases). How might we specify a statistical model for these data? Empirical hazard Smoothed empirical hazards (cancer-specific mortality rates) sts graph, by(distant) hazard kernel(epan2) Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 11 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 12 Smoothed empirical hazards on log scale sts graph, by(distant) hazard kernel(epan2) yscale(log) Fit a Cox model to estimate the mortality rate ratio Empirical hazard.4.8 1.2 1.6.5.1.2.4.8 1.6 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 13 Fitted hazards from Cox model with Efron method for ties ratio: 6.64 stcox distant, efron. stcox distant No. of subjects = 1328 Number of obs = 1328 No. of failures = 7122 Time at risk = 4413.26215 LR chi2(1) = 5544.65 Log likelihood = -61651.446 Prob > chi2 = -------------------------------------------------------------- _t Haz. Ratio Std. Err. z P> z [95% C.I.] --------+----------------------------------------------------- distant 6.64.1689 73. 6.24 6.9 -------------------------------------------------------------- Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 14 Fitted hazards from parametric survival model (exponential) ratio: 14 Ratios Exponential: 14 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 15 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 16

Fitted hazards from parametric survival model (Weibull) Fitted hazards from parametric survival model (Weibull) ratio: 7.41 Ratios Exponential: 14.5 1 1.5 2 2 4 6 8 1 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 17 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 18 Cumulative 1 2 3 4 Fitted cumulative hazards from Weibull model Fitted hazards from Poisson model (yearly intervals) ratio: 6.89 Ratios Exponential: 14 2 4 6 8 1 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 19 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 2 Fitted hazards from Poisson model (3-months) ratio: 6.65 Ratios Exponential: 14 Fitted hazards from Poisson model (months) ratio: 6.64 Ratios Exponential: 14 Poisson (months): 6.64 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 21 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 22 ratio: 6.64 Poisson (rcs 5df for ln(time)) Ratios Exponential: 14 Poisson (months): 6.64 Poisson (spline): 6.65 Fitted hazards from flexible parametric model (5df) ratio: 6.63 Ratios Exponential: 14 Poisson (months): 6.64 Poisson (spline): 6.65 Flexible parametric: 6.63 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 23 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 24

Flexible Parametric Models: Basic Idea Consider a Weibull survival curve. S(t) = exp ( λt γ ) If we transform to the log cumulative hazard scale. ln [H(t)] = ln[ ln(s(t))] ln [H(t)] = ln(λ) + γ ln(t) This is a linear function of ln(t) Introducing covariates gives ln [H(t x i )] = ln(λ) + γ ln(t) + x i β Rather than assuming linearity with ln(t) flexible parametric models use restricted cubic splines for ln(t). Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 25 Survival and Functions Flexible Parametric Models: Incorporating Splines We thus model on the log cumulative hazard scale. ln[h(t x i )] = ln [H (t)] + x i β This is a proportional hazards model. Restricted cubic splines with knots, k, are used to model the log baseline cumulative hazard. ln[h(t x i )] = η i = s (ln(t) γ, k ) + x i β For example, with 4 knots we can write ln [H(t x i )] = η i = γ + γ 1 z 1i + γ 2 z 2i + γ 3 z }{{ 3i } log baseline cumulative hazard + x i β }{{} log hazard ratios Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 26 We are fitting a linear predictor on the log cumulative hazard scale. We can transform to the survival scale S(t x i ) = exp( exp(η i )) The hazard function is a bit more complex. h(t x i ) = ds (ln(t) γ, k ) exp(η i ) dt This involves the derivatives of the restricted cubic splines functions, although these are relatively easy to calculate. Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 27 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 28 Net Survival Relative Survival aims to estimate of net survival. This is the probability of not dying of cancer in the hypothetical world where it is impossible to die of other causes. Key Assumptions Independence between mortality due to cancer and mortality due to other causes & an appropriate estimate of expected survival. Same interpretation/assumption for cause-specific survival. We also assume that we have modelled covariates appropriately. Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 3 Crude and Net Probabilities Net Probability of Death Due to Cancer Crude Probability of Death Due to Cancer = = Probability of death due to cancer in a hypothetical world, where the cancer under study is the only possible cause of death Probability of death due to cancer in the real world, where you may die of other causes before the cancer kills you Net probability also known as the marginal probability. Crude probability also known as the cumulative incidence function. Brief Mathematical Details [6] h(t) = h (t) + λ(t) - all-cause mortality rate h (t) - expected mortality rate λ(t) - excess mortality rate S (t) - Expected Survival R(t) - Relative Survival ( Net Prob of Death = 1 R(t) = 1 exp Crude Prob of Death (cancer) = Crude Prob of Death (other causes) = t t t ) λ(t) S (t)r(t)λ(t) S (t)r(t)h (t) Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 31 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 32

Probabilities of death due to prostate cancer What is cure? Net probability of death (1 relative survival) Net probability of death (1 relative survival) Alive Age 75 at diagnosis 3 7 Alive Age 6 at diagnosis 9 1 Crude probability of death Crude probability of death Dead (other causes) alive Age 75 at diagnosis 9 3 8 Dead (other causes) Alive Age 6 at diagnosis 1 9 Medical cure occurs when all signs of cancer have been removed in a patient; this is an individual-level definition of cure. It is difficult to prove that a patient is medically cured. Population or statistical cure occurs when mortality among patients with the disease returns to the same level as that expected for the general population. Equivalently the excess mortality rate approaches zero. This is a population-level definition of cure. When the excess mortality reaches (and stays) at zero, the relative survival curve is seen to reach a plateau. The inserted numbers represent the 1 year probabilities of death Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 33 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 34 Plateau for relative survival Mixture cure model Mixture cure model S(t) = S (t)(π + (1 π)s u (t)); λ(t) = h (t) + (1 π)fu(t) π+(1 π)s u(t) Relative Survival Years from Diagnosis S (t) is the expected survival. π is the proportion cured (the cure fraction). (1 π) is the proportion uncured (those bound to die ). S u (t) is the net survival for the uncured group. The excess mortality rate has an asymptote at zero. See De Angelis et al. [7], Verdecchia et al. [8] and Lambert et al.[9] for more details. Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 35 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 36 Cure models: Interpreting changes over time Time trends for cancer of the colon age <5 Cure Fraction and Median Survival of Uncured Age Group: <5 Cure Fraction 2.5 Survival of Uncured (c) (a) (d) (b) Cure Fraction Adapted from Verdeccia (1998) (a) General Improvement (b) Selective Improvment (c) Improved palliative care or lead time (d) Inclusion of subjects with no excess risk Cure Fraction Median Survival 2. 1.5 Median Survival 195 196 197 198 199 2 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 37 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 38 Andersson 21 [1]: trends for AML Partitioning Excess Mortality (Eloranta [11]) 2 4 6 8 2 4 6 8 Aged 19 4 at diagnosis 197 198 199 2 Aged 61 7 at diagnosis 197 198 199 2 5 1 1 5 2 2 5 5 1 1 5 2 2 5 Aged 41 6 at diagnosis 2 4 6 8 5 1 1 5 2 2 5 2 4 6 8 197 198 199 2 Aged 71 8 at diagnosis 197 198 199 2 5 1 1 5 2 2 5 We have extended flexible parametric models for relative survival to simultaneously estimate the excess mortality due to diseases of the circulatory system (DCS) and the remaining excess mortality among patients diagnosed with Hodgkin lymphoma. Results are presented both as excess mortality rates and crude probabilities of death. The outcomes (DCS and non-dcs mortality) can be regarded as competing events and the total excess mortality is partitioned using ideas from classical competing risks theory. The model requires population mortality files stratified on cause of death (i.e., DCS and other deaths) to identify those deaths in excess of expected. 95% CI Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 39 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 4

Excess mortality for males with Hodgkin lymphoma Temporal trends in 2-year probability of death Excess Mortality (per 1, p yrs) 25 512 128 32 8 2 5 1 Age at Diagnosis: 19 35 5 1 15 2 Years Since Diagnosis Excess Mortality (per 1, p yrs) 25 512 128 32 8 2 5 1 Age at Diagnosis: 51 65 5 1 15 2 Years Since Diagnosis Excess DCS Mortality Remaining Excess Mortality 95% C.I Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 41 2 year Probability of Death 2 year Probability of Death Age at Diagnosis:3 1973 1976 1979 1982 1985 1988 Age at Diagnosis:6 1973 1976 1979 1982 1985 1988 Dead (Excess DCS Mortality) Dead (Other Causes) Predicted future 2 year Probability of Death Predicted future 2 year Probability of Death Age at Diagnosis:3 1988 1991 1994 1997 2 23 Age at Diagnosis:6 1988 1991 1994 1997 2 23 Dead (Remaining Excess HL Mortality) 95 % CI Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 42 References References 2 [1] Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Statistics in Medicine 24;23:51 64. [2] Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Statistics in Medicine 22;21:2175 2197. [3] Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for relative survival, with application in coronary heart disease. Statistics in Medicine 27; 26:5486 5498. [4] Andersson TML, Dickman PW, Eloranta S, Lambert PC. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol 211;11:96. [5] Reid N. A conversation with Sir David Cox. Statistical Science 1994;9:439 455. [6] Lambert PC, Dickman PW, Nelson CP, Royston P. Estimating the crude probability of death due to cancer and other causes using relative survival models. Statistics in Medicine 21;29:885 895. [7] Angelis RD, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A. Mixture models for cancer survival analysis: application to population-based data with covariates. Statistics in Medicine 1999;18:441 454. [8] Verdecchia A, Angelis RD, Capocaccia R, Sant M, Micheli A, Gatta G, Berrino F. The cure for colon cancer: results from the EUROCARE study. International Journal of Cancer 1998;77:322 329. [9] Lambert PC, Thompson JR, Weston CL, Dickman PW. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 27;8:576 594. [1] Andersson TML, Lambert PC, Derolf AR, Kristinsson SY, Eloranta S, Landgren O, et al.. Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-21, a population-based study. British Journal of Haematology 21;148:918 924. [11] Eloranta S, Lambert PC, Andersson TML, Czene K, Hall P, Björkholm M, Dickman PW. Partitioning of excess mortality in population-based cancer patient survival studies using flexible parametric survival models. BMC Med Res Methodol 212;12:86. Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 43 Paul Dickman Population-Based Cancer Survival FMS, Utö, 24 October 212 44